Russell Investments Group Ltd. Decreases Stock Position in GSK plc (NYSE:GSK)

Russell Investments Group Ltd. trimmed its stake in GSK plc (NYSE:GSK - Free Report) by 1.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,026,840 shares of the pharmaceutical company's stock after selling 10,029 shares during the quarter. Russell Investments Group Ltd.'s holdings in GSK were worth $34,728,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Dorsey & Whitney Trust CO LLC grew its position in GSK by 2.5% during the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 11,506 shares of the pharmaceutical company's stock valued at $389,000 after purchasing an additional 278 shares during the last quarter. Sunbelt Securities Inc. lifted its position in GSK by 73.8% in the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company's stock valued at $29,000 after acquiring an additional 302 shares in the last quarter. Rehmann Capital Advisory Group boosted its position in shares of GSK by 6.3% during the third quarter. Rehmann Capital Advisory Group now owns 5,608 shares of the pharmaceutical company's stock valued at $232,000 after buying an additional 332 shares during the last quarter. GC Wealth Management RIA LLC boosted its holdings in shares of GSK by 2.6% during the 4th quarter. GC Wealth Management RIA LLC now owns 14,009 shares of the pharmaceutical company's stock valued at $474,000 after acquiring an additional 353 shares during the last quarter. Finally, Jacobi Capital Management LLC raised its stake in GSK by 3.9% during the 4th quarter. Jacobi Capital Management LLC now owns 10,403 shares of the pharmaceutical company's stock valued at $352,000 after buying an additional 389 shares during the last quarter. 15.74% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

GSK Stock Performance

NYSE GSK traded up $0.98 on Friday, reaching $34.58. 9,084,647 shares of the stock were exchanged, compared to its average volume of 4,627,785. The company has a current ratio of 0.78, a quick ratio of 0.52 and a debt-to-equity ratio of 1.12. GSK plc has a one year low of $31.72 and a one year high of $45.93. The firm has a market capitalization of $71.35 billion, a PE ratio of 21.75, a PEG ratio of 1.12 and a beta of 0.56. The company's 50-day simple moving average is $37.52 and its two-hundred day simple moving average is $36.22.

GSK (NYSE:GSK - Get Free Report) last released its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, beating analysts' consensus estimates of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. Analysts expect that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, April 10th. Investors of record on Friday, February 21st were paid a dividend of $0.3932 per share. This represents a $1.57 annualized dividend and a yield of 4.55%. The ex-dividend date of this dividend was Friday, February 21st. This is an increase from GSK's previous quarterly dividend of $0.39. GSK's dividend payout ratio (DPR) is 100.63%.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Morgan Stanley began coverage on GSK in a research note on Wednesday, February 12th. They set an "equal weight" rating for the company. StockNews.com raised shares of GSK from a "buy" rating to a "strong-buy" rating in a report on Friday, February 7th. Seven research analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $43.25.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.